Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27


PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallel-group trial.

McCormack S, Ramjee G, Kamali A, Rees H, Crook AM, Gafos M, Jentsch U, Pool R, Chisembele M, Kapiga S, Mutemwa R, Vallely A, Palanee T, Sookrajh Y, Lacey CJ, Darbyshire J, Grosskurth H, Profy A, Nunn A, Hayes R, Weber J.

Lancet. 2010 Oct 16;376(9749):1329-37. doi: 10.1016/S0140-6736(10)61086-0. Epub 2010 Sep 17.


Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.

Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D; CAPRISA 004 Trial Group.

Science. 2010 Sep 3;329(5996):1168-74. doi: 10.1126/science.1193748. Epub 2010 Jul 19. Erratum in: Science. 2011 Jul 29;333(6042):524.


Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.

Austin MN, Rabe LK, Hillier SL.

Sex Transm Dis. 2009 Jun;36(6):368-71. doi: 10.1097/OLQ.0b013e3181972397.


Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial.

Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, Govender S, De Kock A, Cassim N, Palanee T, Dozier G, Maguire R, Lahteenmaki P.

Lancet. 2008 Dec 6;372(9654):1977-87. doi: 10.1016/S0140-6736(08)61842-5.


Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission.

Van Damme L, Govinden R, Mirembe FM, Guédou F, Solomon S, Becker ML, Pradeep BS, Krishnan AK, Alary M, Pande B, Ramjee G, Deese J, Crucitti T, Taylor D; CS Study Group.

N Engl J Med. 2008 Jul 31;359(5):463-72. doi: 10.1056/NEJMoa0707957. Erratum in: N Engl J Med. 2008 Aug 21;359(8):877.


SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria.

Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, Olayemi MO, Wang L, Nanda K, Rountree W.

PLoS One. 2008 Jan 23;3(1):e1474. doi: 10.1371/journal.pone.0001474.


Sensitivity of non-clade B primary HIV-1 isolates to mildly acidic pH.

Connor RI.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):499-501. No abstract available.


Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India.

Smita J, Soma D, Beverly B, Albert P, JoAnn K, Fang G, Missy C, Lydia ST, Anjali P, Arun R, Sanjay M, Steven J R; HIV Prevention Trial Network (HPTN) 047 Protocol Team.

AIDS Res Ther. 2006 Feb 20;3:4.


In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials.

Tien D, Schnaare RL, Kang F, Cohl G, McCormick TJ, Moench TR, Doncel G, Watson K, Buckheit RW, Lewis MG, Schwartz J, Douville K, Romano JW.

AIDS Res Hum Retroviruses. 2005 Oct;21(10):845-53.


Low pH immobilizes and kills human leukocytes and prevents transmission of cell-associated HIV in a mouse model.

Olmsted SS, Khanna KV, Ng EM, Whitten ST, Johnson ON 3rd, Markham RB, Cone RA, Moench TR.

BMC Infect Dis. 2005 Sep 30;5:79.


Some design issues in trials of microbicides for the prevention of HIV infection.

Fleming TR, Richardson BA.

J Infect Dis. 2004 Aug 15;190(4):666-74. Epub 2004 Jul 20.


Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women.

Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT, Day J, Welch J, Rosenberg Z; HIV Prevention Trials Network (HPTN) 020 Protocol Team.

AIDS. 2003 Feb 14;17(3):321-9.


Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial.

Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, Sirivongrangson P, Mukenge-Tshibaka L, Ettiègne-Traoré V, Uaheowitchai C, Karim SS, Mâsse B, Perriëns J, Laga M; COL-1492 Study Group.

Lancet. 2002 Sep 28;360(9338):971-7. Erratum in: Lancet 2002 Dec 7;360(9348):1892.


Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial.

Roddy RE, Zekeng L, Ryan KA, Tamoufé U, Tweedy KG.

JAMA. 2002 Mar 6;287(9):1117-22.


'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV(89.6PD) in vitro and in vivo.

Weber J, Nunn A, O'Connor T, Jeffries D, Kitchen V, McCormack S, Stott J, Almond N, Stone A, Darbyshire J.

AIDS. 2001 Aug 17;15(12):1563-8.


Tests of Buffergel for contraception and prevention of sexually transmitted diseases in animal models.

Zeitlin L, Hoen TE, Achilles SL, Hegarty TA, Jerse AE, Kreider JW, Olmsted SS, Whaley KJ, Cone RA, Moench TR.

Sex Transm Dis. 2001 Jul;28(7):417-23.


Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial.

Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, Bwayo J, Ndinya-Achola J, Kreiss JK.

Sex Transm Dis. 2001 Jul;28(7):394-400.


Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites.

van De Wijgert J, Fullem A, Kelly C, Mehendale S, Rugpao S, Kumwenda N, Chirenje Z, Joshi S, Taha T, Padian N, Bollinger R, Nelson K.

J Acquir Immune Defic Syndr. 2001 Jan 1;26(1):21-7.


Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.

Mayer KH, Peipert J, Fleming T, Fullem A, Moench T, Cu-Uvin S, Bentley M, Chesney M, Rosenberg Z.

Clin Infect Dis. 2001 Feb 1;32(3):476-82. Epub 2001 Jan 26.


Acceptability of a novel vaginal microbicide during a safety trial among low-risk women.

Bentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, Mayer KH.

Fam Plann Perspect. 2000 Jul-Aug;32(4):184-8.

Supplemental Content

Support Center